The different inhibitory domains of the Oct-2 transcription factor have distinct functional activities  by Gay, Robert D. et al.
FEBS 19332 FEBS Letters 416 (1997) 135-138 
The different inhibitory domains of the Oct-2 transcription factor have 
distinct functional activities 
Robert D. Gay, Sally J. Dawson, David S. Latchman* 
The Windeyer Institute for Medical Sciences, Department of Molecular Pathology, University College London Medical School, The Windeyer Building, 
46 Cleveland Street, London W1P 6DB, UK 
Received 18 July 1997; revised version received 9 September 1997 
Abstract The Oct-2 POU family transcription factor contains 
three distinct regions whose deletion reduces its ability to inhibit 
transcription via its octamer binding site. Here we show that only 
one of these inhibitory domains is capable of also inhibiting the 
activity of activating molecules bound at adjacent sites upstream 
of a TATA box-containing promoter whereas the other two 
regions are inactive in this assay. None of the three regions is 
able to achieve this effect when located upstream of the same 
promoter containing an initiator motif. The mechanisms of 
action of these domains and their role in the functioning of the 
Oct-2 factor are discussed. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The Oct-2 transcription factor is a member of the POU 
family of transcription factors which was originally identified 
as a factor specifically expressed in B lymphocytes [1,2]. In 
these cells, Oct-2 appears to have a generally stimulatory ef-
fect on the expression of specific genes. Thus, the early sug-
gestion that Oct-2 may play a role in activating the immuno-
globulin genes which contain its target octamer sequence 
ATGCAAAT in their promoters and enhancers [3] has now 
been supplemented by the demonstration that mice in which 
the gene encoding Oct-2 has been inactivated lack expression 
of some B cell-specific genes such as CD36 [4] and Crisp3 [5]. 
Indeed, these knock-out mice lacking functional Oct-2 show 
defects in B cell maturation which indicates the critical role of 
Oct-2 in this process [6]. These stimulatory effects on gene 
expression appear to be mediated by a C-terminal activation 
domain which is present in the predominant B cell form of 
Oct-2, Oct-2.1 [7,8]. 
Although absent in most non-B cell types, Oct-2 has been 
identified in neuronal cells [9-11]. In these cells, Oct-2 appears 
to have a predominantly inhibitory effect on gene expression 
repressing, for example, the expression of the tyrosine hydrox-
ylase gene which also contains an octamer motif in its pro-
moter [12]. Interestingly, alternative splicing of the primary 
transcript produced by the single gene encoding Oct-2 results 
in the production of a number of different mRNAs encoding 
different isoforms of the protein [13]. This effect occurs in a 
tissue-specific manner so that the predominant forms of Oct-2 
in neuronal cells, Oct-2.4 and Oct-2.5, lack the C-terminal 
activation domain present in the predominant B cell form, 
Oct-2.1, but are identical at the N-terminus of the protein [14]. 
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These findings have led to a detailed study of the N-termi-
nus of the Oct-2 molecule in order to identify specific regions 
common to all the forms of Oct-2 which might mediate an 
inhibitory effect on gene expression in the absence of the C-
terminal activation domain present in Oct-2.1 but not in Oct-
2.4 or 2.5. In particular, our laboratory defined a 40 amino 
acid region (amino acids 142-181) whose deletion from intact 
Oct-2 abolished its ability to inhibit gene expression [15]. 
When linked to the DNA binding domain of the heterologous 
Gal4 transcription factor, this domain was able to repress 
transcription from promoters containing binding sites for 
GAL4 indicating that it functions as a transferable inhibitory 
domain [16]. Moreover, when linked in this manner to a het-
erologous DNA binding domain, this inhibitory domain can 
also inhibit gene activation by a wide variety of different ac-
tivation domains delivered to another DNA binding site in the 
promoter [17]. Thus this inhibitory domain is likely to act 
downstream of these activation domains presumably by inter-
acting with a component of the basal transcriptional complex 
[17]. 
In addition to this domain, other studies have located an N-
terminal inhibitory domain between amino acids 42 and 64 of 
Oct-2.1 [18,19]. This domain was demonstrated to inhibit the 
activity of the C-terminal activation domain of Oct-2 when 
fused to it in an artificial construct containing, in addition, the 
DNA binding domain of Gal4 [18,19]. The effect of this do-
main on the ability of either the C-terminal activation domain 
of Oct-2 or other activation domains when delivered to the 
promoter in trans (i.e. via a distinct DNA binding site in the 
promoter) was not reported, however. 
Although both these inhibitory domains are present in all 
the different isoforms of Oct-2 [13], an additional inhibitory 
domain has also been defined which is unique to the Oct-2.3 
isoform [20]. This isoform resembles Oct-2.1 at the C-terminus 
but differs from it in containing an additional 22 amino acids 
at the N-terminus between positions 72/73 of Oct-2.1. The 
presence of this domain was associated with a much weaker 
activation of transcription by Oct-2.3 compared to Oct-2.1 
[13]. Subsequently, however, this domain was shown to be 
unable to activate the C-terminal activation domain when 
linked to it in eis in a construct containing the DNA binding 
domain of GAL4 [20]. Its effect on other activation domains 
or on the Oct-2 C-terminal domain when delivered to the 
promoter in trans was not assessed in these experiments how-
ever. 
In order to directly compare the activity of the two inhib-
itory domains defined by other laboratories with that ob-
served for the domain we previously defined, we have tested 
these two other domains for their ability to inhibit activation 
by a wide variety of activators when delivered to the promoter 
in trans utilising the same system which we previously used to 
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characterise the inhibitory domain defined by our laboratory 
[17]. 
2. Materials and methods 
2.1. Repressor domain cloning 
The inhibitory domain defined by our laboratory (designated II) 
was linked to the DNA binding domain of the tetracycline repressor 
as previously described [17]. In order to clone the inhibitory domain 
located between amino acids 42 and 64 of Oct-2.1 (designated 12) and 
the inhibitory domain which is unique to Oct-2.3 and is located be-
tween amino acids 72/73 of Oct-2.3 (designated 13), PCR primers were 
used to amplify the region containing amino acids 42-99 (numbered 
for Oct-2.1) from either Oct-2.1 or Oct-2.3. The primers used were 
5'-GAATTCCATCAGAACCCCCAGAATAAAG-3' and 5'-GAAT-
CCTAGCTGGCTGCCCGTCAGC-3'. When these primers were 
used to amplify a plasmid encoding Oct-2.1, we obtained the expected 
183 bp insert. Similarly, when amplification was carried out using a 
plasmid encoding Oct-2.3 a 249 bp insert containing the additional 
66 bp sequence found in this isoform as well as the region encoding 
amino acids 42-99 of Oct 2.1 was obtained. Each of these fragments 
was then cloned into the pTETr plasmid containing the tetracycline 
repressor DNA binding domain and the clones obtained verified by 
DNA sequence analysis. 
2.2. Transfections 
BHK-21 fibroblast cells [21] and ND7 neuronal cells [22] were co-
transfected by the method of Gorman [23]. In each case 5 u\g of each 
repressor domain construct was co-transactivated with 5 ug of plas-
mid encoding a specific activator domain linked to the DNA binding 
domain of GAL4 and 5 iig of the reporter construct. Activator and 
reporter constructs have been previously described [17,24]. In partic-
ular, each reporter contains seven binding sites for the TET repressor 
DNA binding domain upstream of five binding sites for GAL4 which 
in turn is located upstream of either a TATA box or an initiator 
motif. In all cases chloramphenicol acetyltransferase (CAT) activity 
was determined by the method of Gorman [23] with all samples being 
equalised on the basis of DNA uptake as assayed by dot blotting 
transfected cell extracts with an ampicillin-resistant gene probe de-
rived from the plasmid vector [25]. In CAT assays an amount of 
extract which would give approximately 15-30% conversion (as as-
sayed in preliminary experiments) was used for the sample lacking any 
inhibitor domain and the activity compared to an equivalent amount 
of the other samples. This allows repression to be detected whilst 
remaining in the linear range of the CAT assay. 
inhibitory domains upon this activation domain when deliv-
ered to the DNA in trans. Thus the TATA box reporter plas-
mid was co-transfected with a construct containing one of the 
inhibitory domains linked to the TET repressor DNA binding 
domain and a construct encoding the Oct-2 C-terminal acti-
vation domain linked to the Gal4 DNA binding domain. In 
this experiment (Fig. 1A) the inhibitory domain which we 
previously characterised (II) was able to repress activation 
by the Gal4 activation domain when delivered to the DNA 
in trans by transfection of ND7 neuronal cells whereas neither 
the inhibitory domain 12 nor the same domain linked to the 
Oct-2.3 domain (13) was able to achieve this effect. 
We have previously demonstrated that the Oct-2 II domain 
is cell type-specific in its activity having a particularly strong 
effect in neuronal cells [16]. It was therefore possible that the 
lack of inhibitory effect observed with the other domains was 
due to their similarly have a cell type-specific effect, although 
in this case being inactive in cells of neuronal origin. Similarly, 
it was possible that their inhibitory effect was in some way 
masked by the presence of endogenous Oct-2 in ND7 cells [11] 
which might be, for example, binding any co-factors required 
for the inhibitory effect. We therefore carried out similar ex-
periments in BHK fibroblast cells which lack endogenous Oct-
3. Results and discussion 
In our previous experiments [17] we used a reporter con-
struct containing seven binding sites for the tetracycline re-
pressor DNA binding domain located upstream of five bind-
ing sites for the GAL4 DNA binding domain which in turn 
were located upstream of a TATA box and CAT reporter 
gene. It was therefore possible to assess the effect of our in-
hibitory domain on transcription by a variety of activators by 
linking this domain to the TET repressor DNA binding do-
main and co-transfecting the reporter with this construct and 
a variety of activation domains linked to the GAL4 DNA 
binding domain. We therefore prepared similar constructs 
containing the Oct-2.1 inhibitory domain defined by Friedl 
and Matthias between amino acids 42 and 64 of Oct-2.1 
[18,19] which we designated 12 and the same region together 
with the inhibitory domain unique to Oct-2.3 [20] which we 
designated 13. The inhibitory domain construct previously 
prepared by our laboratory was designated II. 
As the 12 but not the Oct-2.3 inhibitory domain had pre-
viously been shown to inhibit the activity of the C-terminal 
activation domain of Oct-2, when linked to it in eis via the 
Gal4 DNA binding domain we tested the effect of all three 
Fig. 1. Choloramphenicol acetyl transferase (CAT) assay following 
transfection of ND7 neuronal cells (A) and BHK fibroblast cells (B) 
with the T7 G5-TATA-CAT reporter construct together with a con-
struct containing the C-terminal activation domain of Oct-2 linked 
to the DNA binding domain of GAL4 and either vector expressing 
the isolated DNA binding domain of the tetracycline repressor (V) 
or the same vector expressing the DNA binding domain linked to 
each of the three distinct inhibitory domains previously defined 
within the Oct-2 molecule. In each case the degree of activation ob-
tained by co-transfection of the activator is compared to that ob-
served by co-transfection of the activator with the reporter and the 
vector construct lacking any insert (set at 100%). Values are the 
average of three independent experiments whose standard error is 
indicated by the bars. 
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Fig. 2. CAT assay indicating the effect of the various inhibitory do-
mains on activation of the T7 G5-TATA-CAT construct by expres-
sion vectors containing the Gal4 DNA binding domain linked to 
the activation domains of either VP16 (A), NFKB (B) or Spl (C). 
In each case the degree of activation is compared to that observed 
with that activation domain upon co-transfection of the reporter 
and TET repressor DNA binding domain construct in the absence 
of any linked inhibitory domain. Values are the average of three ex-
periments whose standard error is shown by the bars. 
2. As illustrated in Fig. IB, the effect of the II domain was 
very weak in this situation in accordance with our previous 
experiments and similarly, no effect of the other inhibitory 
domains was observed. Hence it appears that unlike the II 
inhibitory domain neither of the other inhibitory domains is 
able to repress gene activation by the Oct-2 C-terminal do-
main when delivered to the DNA in trans in either neuronal 
or non-neuronal cell types. Indeed the 13 construct appeared 
to have a weak activating effect on gene expression in this 
system. 
To determine whether this lack of effect of these domains 
was unique to the Oct-2 C-terminal domain which is rich in 
proline residues we carried out similar experiments with other 
activation domains. In these experiments the inhibitory do-
mains similarly had no inhibitory effects on activation by 
the acidic activation domains of VP16 (Fig. 2A) or N F K B 
(Fig. 2B) or the glutamine-rich activation domain of Spl 
(Fig. 2C). 
Indeed the only effect observed was a stimulation of the 
activation effect which was observed for both 12 and 13 in 
individual cases. As expected the II inhibitory domain re-
pressed the activity of all the activators in accordance with 
our previous experiments [17]. A similar lack of inhibitory 
effect on other activators was also observed in similar experi-
ments involving the proline-rich activation domain of CTF, 
the acidic activation domain of E1A and the Hob motif con-
tained within the N-terminal region of c-Fos (data not 
shown). 
Hence the inhibitory domain 12 and the same domain 
linked to the inhibitory domain of Oct-2.3 in 13 are unable 
to repress the activity of a wide variety of activation domains 
of different classes when delivered to the DNA in trans 
although the inhibitory domain II which we previously de-
fined can do so. 
Interestingly, however, we previously showed [17] that the 
ability of the II inhibitory domain to achieve this effect is 
abolished when the TATA box in the test promoter is re-
placed by an initiator element [17]. We therefore tested, 
whether in contrast to II, either of the other domains could 
mediate repression of gene activation by an activator on a 
promoter using an initiator element. Similar transfections 
were therefore carried out using a target promoter in which 
the TATA box used in our previous experiments had been 
replaced by an initiator element [17,24]. In these experiments 
(Fig. 3) neither of the constructs was able to repress activation 
of this initiator-containing promoter by either the acidic acti-
vation domain of VP16 or the glutamine-rich domain of Spl. 
Thus these domains are incapable of repressing activation 
regardless of whether the promoter tested contained a 
TATA box or an initiator motif. 
These findings therefore establish distinct functional differ-
ences between the different inhibitory domains that have been 
defined within the Oct-2 molecule and indicate that they are 
likely to have distinctly different roles in the functioning of 
this factor. Thus the 12 inhibitory domain defined by Friedl 
and Matthias between amino acids 42 and 64 of Oct-2.1 
[18,19] appears to be able to repress the C-terminal activation 
Fig. 3. CAT assay indicating the effect of the Oct-2 repressor do-
mains on activation of a T7 G5-Initiator-CAT construct by Gal4-
Spl (solid bars) or Gal4-Vpl6 (hatched bars). In each case the de-
gree of activation observed is compared to that observed with the 
reporter construct, the appropriate activator and the construct ex-
pressing the DNA binding domain of the tetracycline repressor 
alone (set at 100%). 
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domain only when linked to it in eis either naturally or with a 
heterologous DNA binding domain. It is incapable, however, 
of repressing this activation domain or other activation do-
mains in trans. This domain is therefore likely only to act to 
reduce the activation ability of Oct-2 in particular situations 
when it is bound to its binding site on specific gene promoters. 
The activity of the inhibitory domain unique to Oct-2.3 as 
defined by Annweiler et al. [20] is even more restricted since it 
only acts within the context of intact Oct-2 and is inactive 
even against its own C-terminal domain when linked to it 
via a heterologous DNA binding domain [20]. Similarly, we 
have demonstrated that when linked to the 12 domain, the 
construct containing this domain is still inactive in inhibiting 
activation by the C-terminal activation domain of Oct-2 or 
other activation domains when delivered to the DNA in trans. 
The activity of the Oct-2.3 domain is therefore likely to be 
confined to specifically reducing the activation ability of Oct-
2.3 and perhaps as suggested by Annweiler et al. [20], it may 
compete for binding with other more potent activating forms 
of Oct-2 thereby reducing the activation mediated by an Oct-2 
binding site when this factor is present. Hence Oct-2.3 may act 
as a passive repressor which is able to reduce the rate of gene 
expression by blocking the binding of more potent activators 
to its binding site. 
In contrast, the II inhibitory domain which we previously 
defined [15,17] is not only capable of producing this effect but 
can also allow Oct-2 to act as a direct repressor which reduces 
the activity of a promoter compared to that which would be 
observed in the absence of its specific DNA binding site. 
Hence this factor is able to interfere with gene activation by 
other positively acting factors bound at adjacent sites and is 
therefore likely to be responsible for the ability of Oct-2 to 
dramatically reduce the rate of transcription of some pro-
moters such as that encoding tyrosine hydroxylase [12]. 
The ability of this domain to block the activity of a wide 
variety of activators in this way is likely to be dependent upon 
its ability to interact with the basal transcriptional complex 
and reduce its activity thereby acting downstream of the dif-
ferent classes of activators. Although further studies will be 
required to define the target of the II inhibitory domain in the 
basal transcriptional complex it is already clear that this do-
main is far more potent that the other inhibitory domains 
defined within the Oct-2 molecule and is likely to be respon-
sible for the direct inhibitory effect of the Oct-2 factor tran-
scription in neuronal cells. 
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